Novartis AG ADR (NVS)vsRoyalty Pharma Plc (RPRX)
NVS
Novartis AG ADR
$156.08
+3.20%
HEALTHCARE · Cap: $286.29B
RPRX
Royalty Pharma Plc
$65.93
+1.71%
HEALTHCARE · Cap: $37.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2136% more annual revenue ($56.69B vs $2.54B). RPRX leads profitability with a 32.0% profit margin vs 22.5%. RPRX appears more attractively valued with a PEG of 1.51. RPRX earns a higher WallStSmart Score of 55/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RPRX
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.2%
Fair Value
$93.84
Current Price
$156.08
$62.24 premium
Margin of Safety
-73.5%
Fair Value
$37.37
Current Price
$65.93
$28.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while RPRX is a growth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.47 — expect wider price swings.
RPRX is growing revenue faster at 16.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (55/100 vs 51/100), backed by strong 32.0% margins and 16.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?